Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial

医学 射血分数 心室流出道 内科学 心脏病学 肥厚性心肌病 队列 心肌病 冲程容积 前瞻性队列研究 心力衰竭
作者
Stephen B. Heitner,Daniel Louis Jacoby,Steven J. Lester,ANJALI TIKU OWENS,Andrew Wang,David Zhang,Joseph L. Lambing,June Lee,Marc J. Semigran,Amy J. Sehnert
出处
期刊:Annals of Internal Medicine [American College of Physicians]
卷期号:170 (11): 741-748 被引量:314
标识
DOI:10.7326/m18-3016
摘要

Background: Mavacamten, an orally administered, small-molecule modulator of cardiac myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic cardiomyopathy (oHCM). Objective: To characterize the effect of mavacamten on left ventricular outflow tract (LVOT) gradient. Design: Open-label, nonrandomized, phase 2 trial. (ClinicalTrials.gov: NCT02842242). Setting: 5 academic centers. Participants: 21 symptomatic patients with oHCM. Intervention: Patients in cohort A received mavacamten, 10 to 20 mg/d, without background medications. Those in cohort B received mavacamten, 2 to 5 mg/d, with β-blockers allowed. Measurements: The primary end point was change in postexercise LVOT gradient at 12 weeks. Secondary end points included changes in peak oxygen consumption (pVO2), resting and Valsalva LVOT gradients, left ventricular ejection fraction (LVEF), and numerical rating scale dyspnea score. Results: In cohort A, mavacamten reduced mean postexercise LVOT gradient from 103 mm Hg (SD, 50) at baseline to 19 mm Hg (SD, 13) at 12 weeks (mean change, -89.5 mm Hg [95% CI, -138.3 to -40.7 mm Hg]; P = 0.008). Resting LVEF was also reduced (mean change, -15% [CI, -23% to -6%]). Peak VO2 increased by a mean of 3.5 mL/kg/min (CI, 1.2 to 5.9 mL/kg/min). In cohort B, the mean postexercise LVOT gradient decreased from 86 mm Hg (SD, 43) to 64 mm Hg (SD, 26) (mean change, -25.0 mm Hg [CI, -47.1 to -3.0 mm Hg]; P = 0.020), and mean change in resting LVEF was -6% (CI, -10% to -1%). Peak VO2 increased by a mean of 1.7 mL/kg/min (SD, 2.3) (CI, 0.03 to 3.3 mL/kg/min). Dyspnea scores improved in both cohorts. Mavacamten was well tolerated, with mostly mild (80%), moderate (19%), and unrelated (79%) adverse events. The most common adverse events definitely or possibly related to mavacamten were decreased LVEF at higher plasma concentrations and atrial fibrillation. Limitation: Small size; open-label design. Conclusion: Mavacamten can reduce LVOT obstruction and improve exercise capacity and symptoms in patients with oHCM. Primary Funding Source: MyoKardia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ming完成签到,获得积分10
刚刚
刚刚
1秒前
史文韬发布了新的文献求助10
1秒前
科研通AI6.3的应助被大方的契采纳,获得10
2秒前
2秒前
不管啦发布了新的文献求助10
2秒前
2秒前
无敌大裤衩完成签到,获得积分10
3秒前
CT完成签到,获得积分10
3秒前
4秒前
愚者发布了新的文献求助10
4秒前
纪秋完成签到 ,获得积分10
5秒前
Ellalala完成签到 ,获得积分10
5秒前
CipherSage的应助被师专第一黑奴采纳,获得10
6秒前
6秒前
6秒前
6秒前
科研通AI6.2的应助被Waitcy采纳,获得10
6秒前
霸气乐菱发布了新的文献求助10
7秒前
7秒前
8秒前
彩色青亦发布了新的文献求助10
8秒前
8秒前
果冻完成签到 ,获得积分10
9秒前
10秒前
11秒前
xushuqi给xushuqi的求助进行了留言
11秒前
cloudss完成签到,获得积分10
12秒前
勿语发布了新的文献求助10
13秒前
自信易槐完成签到,获得积分10
13秒前
Zhang发布了新的文献求助10
13秒前
科研通AI6.3的应助被dudu采纳,获得10
13秒前
14秒前
自由的百川完成签到 ,获得积分10
14秒前
14秒前
花花发布了新的文献求助10
15秒前
15秒前
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194415
求助须知:如何正确求助?哪些是违规求助? 9580155
关于积分的说明 21870088
捐赠科研通 7793967
什么是DOI,文献DOI怎么找? 3437647
关于科研通互助平台的介绍 2560986
邀请新用户注册赠送积分活动 2484376